Abstract
In this study, the detailed DNA sequence specificity of four acridine Pt complexes was examined and compared with that of cisplatin. The DNA sequence specificity was determined in a telomere-containing DNA sequence using a polymerase stop assay, with a fluorescent primer and an automated capillary DNA sequencer. The Pt compounds included an acridine intercalating moiety that was modified to give a 9-aminoacridine derivative, a 7-methoxy-9-aminoacridine derivative, a 7-fluoro-9-aminoacridine derivative and a 9-ethanolamine-acridine derivative. Compared with cisplatin, the DNA sequence specificity was most altered for the 7-methoxy-9-aminoacridine compound, followed by the 9-aminoacridine derivative, the 7-fluoro-9-aminoacridine compound and the 9-ethanolamine-acridine derivative. The DNA sequence selectivity for the four acridine Pt complexes was shifted away from runs of consecutive guanines towards single guanine bases, especially 5′-GA dinucleotides and sequences that contained 5′-CG. The sequence specificity was examined in telomeric and non-telomeric DNA sequences. Although it was found that telomeric DNA sequences were extensively damaged by the four acridine Pt complexes, there was no extra preference for telomeric sequences.
Similar content being viewed by others
Abbreviations
- 9AmAcPtCl2 :
-
Dichlorido(N-2-[(2-aminoethyl)amino]-ethyl)-9-aminoacridine-4-carboxamide)platinum(II)
- 7-Methoxy-9AmAcPtCl2 :
-
Dichlorido(N-2-[(2-aminoethyl)amino]-ethyl)-7-methoxy-9-aminoacridine-4-carboxamide)platinum(II)
- 7-Fluoro-9AmAcPtCl2 :
-
Dichlorido(N-2-[(2-aminoethyl)amino]-ethyl)-7-fluoro-9-aminoacridine-4-carboxamide)platinum(II)
- 9-Ethanolamine-AcPtCl2 :
-
Dichlorido(N-2-[(2-aminoethyl)amino]-ethyl)-9-ethanolamine-acridine-4-carboxamide)platinum(II)
- CE-LIF:
-
Capillary electrophoresis with laser-induced-fluorescence detection
- Cisplatin:
-
cis-Diamminedichloridoplatinum(II)
- DMF:
-
Dimethylformamide
- Tris:
-
Tris(hydroxymethyl)aminomethane
References
Loehrer PJ, Einhorn LH (1984) Ann Intern Med 100:704–713
Kelland LR (2007) Nat Rev Cancer 7:573–584
Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ (1992) Proc Natl Acad Sci USA 89:2307–2311
Jamieson ER, Lippard SJ (1999) Chem Rev 99:2467–2498
Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) Biochemistry 24:707–713
Wang D, Lippard SJ (2005) Nat Rev Drug Discov 4:307–320
Jung YW, Lippard SJ (2007) Chem Rev 107:1387–1407
Ponti M, Forrow SM, Souhami RL, D’Incalci M, Hartley JA (1991) Nucleic Acids Res 19:2929–2933
Murray V, Motyka H, England PR, Wickham G, Lee HH, Denny WA, McFadyen WD (1992) J Biol Chem 267:18805–18809
Murray V (2000) Prog Nucleic Acid Res Mol Biol 63:367–415
Denny WA (1989) Anticancer Drug Des 4:241–263
Whittaker JK, McFadyen WD, Wickham G, Wakelin LPG, Murray V (1998) Nucleic Acids Res 26:3933–3939
Temple MD, McFadyen WD, Holmes RJ, Denny WA, Murray V (2000) Biochemistry 39:5593–5599
Carland M, Grannas MJ, Cairns MJ, Roknic VJ, Denny WA, McFadyen WD, Murray V (2010) J Inorg Biochem 104:815–819
Whittaker JK, McFadyen WD, Baguley BC, Murray V (2001) Anticancer Drug Des 16:81–89
Temple MD, Recabarren P, McFadyen WD, Holmes RJ, Denny WA, Murray V (2002) Biochim Biophys Acta 1574:223–230
Lee HH, Palmer BD, Baguley BC, Chin M, McFadyen WD, Wickham G, Thorsbourne-Palmer D, Wakelin LPG, Denny WA (1992) J Med Chem 35:2983–2987
Holmes RJ, McKeage MJ, Murray V, Denny WA, McFadyen WD (2001) J Inorg Biochem 85:209–217
Murray V (1989) Nucl Acids Res 17:8889
Paul M, Murray V (2011) Biomed Chromatogr (in press)
Viscardi V, Clerici M, Cartagena-Lirola H, Longhese MP (2005) Biochimie 87:613–624
Henderson ER, Blackburn EH (1989) Mol Cell Biol 9:345–348
Cesare AJ, Reddel RR (2010) Nat Rev Genet 11:319–330
Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR (1988) Proc Natl Acad Sci USA 85:6622–6626
Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW (1997) Genes Dev 11:2801–2809
Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T (1999) Cell 97:503–514
Yu HQ, Miyoshi D, Sugimoto N (2006) J Am Chem Soc 128:15461–15468
Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S (2006) Nucleic Acids Res 34:5402–5415
Nelson SM, Ferguson LR, Denny WA (2004) Cell Chromosome 3:2–27
Reed JE, Neidle S, Vilar R (2007) Chem Commun 42:4366–4368
Burstyn JN, Heiger-Bernays WJ, Cohen SM, Lippard SJ (2000) Nucleic Acids Res 28:4237–4243
Brabec V (2002) Prog Nucleic Acid Res Mol Biol 71:1–68
Adams A, Guss M, Collyer C, Denny WA, Wakelin LPG (1999) Biochemistry 38:9221–9233
Acknowledgments
Support of this work by the University of New South Wales Science Faculty Research Grant Scheme is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paul, M., Murray, V. The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. J Biol Inorg Chem 16, 735–743 (2011). https://doi.org/10.1007/s00775-011-0774-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-011-0774-y